Several: Now that we have studies showing that long-term benefits for interferons and Copaxone are likely minimal at best, and that 60% of pts do not do well by 2 yrs, we are starting to see the emergence of far more potent meds. Gilenya and tysabri (natalizumab) are here. Tecfedera is close, lemtrada by end of year. Daclizumab, ocrelizumab, the newer s-1-p drugs being looked at. Even new drug for spasticity.
Answered 6/25/2014
5.3k views
A doctor has provided 1 answer
A doctor has provided 1 answer
5 doctors weighed in across 2 answers
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question